文献速递姑息放疗与转移瘤放疗物理与技术

立体定向体部放疗与三维适形放疗对脊柱转移瘤患者疼痛缓解的随机II期试验

Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy.
PubMed 文献 · Radiother Oncol · 2018-05-26

这项单中心、非盲法、随机探索性试验分析了55例组织学或影像学证实的疼痛性脊柱转移瘤患者,按1:1随机接受单次立体定向体部放疗(24 Gy)或三维适形放疗(30 Gy分10次)。主要终点为放疗完成后3个月照射区域内视觉模拟评分(VAS)改善>2分。尽管3个月时两组VAS无显著差异(p=0.13),但立体定向体部放疗组疼痛值下降更快(p=0.01),6个月时VAS显著更低(p=0.002),疼痛缓解在6个月时显著更优(p=0.003)。

要点

  • 立体定向体部放疗组3个月内疼痛VAS下降更快(p=0.01),6个月时VAS显著低于三维适形放疗组(p=0.002)。
  • 3个月时疼痛缓解有改善趋势(p=0.057),6个月时显著改善(p=0.003)。
  • 立体定向体部放疗组无患者发生≥3级毒性(依据常见不良事件评价标准v4.03)。

核心结论

  • 这项随机试验表明姑息性立体定向体部放疗对脊柱转移瘤有效,与更快和更好的疼痛缓解相关。
  • 作者指出更大规模的正在进行的随机研究将有助于进一步探讨这些终点。

研究设计与样本

  • 单中心、非盲法、随机探索性试验,纳入55例组织学或影像学证实的疼痛性脊柱转移瘤患者。
  • 参与者按1:1随机接受单次立体定向体部放疗(24 Gy)或三维适形放疗(30 Gy分10次)。
  • 主要终点为放疗完成后3个月照射区域内视觉模拟评分(VAS)改善>2分;采用意向性治疗分析;试验注册号NCT02358720。

主要发现

  • 3个月时两组VAS无显著差异(p=0.13),但立体定向体部放疗组在此期间疼痛值下降更快(p=0.01)。
  • 放疗后6个月,立体定向体部放疗组VAS值显著更低(p=0.002)。
  • 3个月(p=0.761)和6个月(p=0.174)时两组口服吗啡等效剂量(OMED)消耗无差异。
  • 3个月时立体定向体部放疗组疼痛缓解有改善趋势(p=0.057),6个月时显著改善(p=0.003)。
  • 立体定向体部放疗组无患者发生≥3级毒性(依据常见不良事件评价标准v4.03)。

关键数值与推荐

  • 疼痛缓解定义为放疗完成后3个月照射区域内VAS改善>2分。
  • 疼痛反应按国际骨共识反应定义评估。
  • 立体定向体部放疗方案为单次24 Gy;三维适形放疗方案为30 Gy分10次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To report the primary endpoint of a randomized trial comparing pain response following palliative stereotactic body radiation therapy (SBRT) versus conventionally-fractionated 3D-conformal radiotherapy (3DCRT) for previously untreated spinal metastases. METHODS: Fifty-five patients with histologically/radiologically confirmed painful spinal metastases were analyzed in this single-institutional, non-blinded, randomized explorative trial. Participants were randomly assigned (1:1) to receive single-fraction SBRT (24 Gy) or 3DCRT (30 Gy in 10 fractions). The primary endpoint was pain relief of >2 points on the visual analog scale (VAS) measured within the irradiated region at 3 months following radiotherapy completion. Other recorded parameters included pain response (per International Bone Consensus response definitions), use of concurrent medications and opioid usage (oral morphine equivalent dose, OMED). All parameters were assessed at baseline and at three and six months after RT. Intention-to-treat analysis was applied. This trial is registered with ClinicalTrials.gov, number NCT02358720. FINDINGS: Despite no significant differences for VAS at 3 months between groups (p = 0.13), pain values decreased faster within this time period in the SBRT arm (p = 0.01). At 6 months following RT, significantly lower VAS values were reported in the SBRT group (p = 0.002). There were no differences in OMED consumption at 3 (p = 0.761) and 6 months (p = 0.174). There was a trend toward improved pain response in the SBRT arm at 3 months (p = 0.057), but significantly so after 6 months (p = 0.003). No patient in the SBRT group experienced grade ≥3 toxicities according to the Common Terminology Criteria for Adverse Events v.4.03. CONCLUSIONS: This randomized trial demonstrates the utility of palliative SBRT for spinal metastases, which was associated with a quicker and improved pain response. Larger ongoing randomized studies will assist in further addressing these endpoints.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sprave T, Verma V, Förster R, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2018. PMID: 29843899. doi:10.1016/j.radonc.2018.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。